Conjugation of ATIII-binding pentasaccharides to extend the half-life of proteins: Long-acting insulin

被引：14

作者：

de Kort, Martin ^{[1
]}

Gianotten, Bas ^{[1
]}

Wisse, Jeffry A. J. ^{[1
]}

Bos, Ebo S. ^{[2
]}

Eppink, Michel H. M. ^{[3
]}

Mattaar, Ellen ^{[4
]}

Vogel, Gerard M. T. ^{[2
]}

Dokter, Wim H. A. ^{[2
]}

Honing, Maarten ^{[1
]}

Vonsovic, Stanislava ^{[1
]}

Smit, Martin-Jan ^{[4
]}

Wijkmans, Jac C. H. M. ^{[1
]}

van Boeckel, Constant A. A. ^{[1
]}

机构：

[1] Schering Plough Corp, NV Organon, Dept Med Chem, NL-5340 BH Oss, Netherlands

[2] Schering Plough Corp, NV Organon, Dept Pharmacol, NL-5340 BH Oss, Netherlands

[3] Schering Plough Corp, NV Organon, Dept API BT, NL-5340 BH Oss, Netherlands

[4] Schering Plough Corp, NV Organon, Dept Mol Pharmacol, NL-5340 BH Oss, Netherlands

来源：

CHEMMEDCHEM | 2008年 / 3卷 / 08期

关键词：

antithrombin III; glycoconjugates; insulin; oligosaccharides; protein modifications;

D O I：

10.1002/cmdc.200800053

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

CarboCarrier™: Site-specific conjugation of insulin to a synthetic antithrombin III (ATIII)-binding pentasaccharide (PS) improves the protein's half-life and extends the duration of action. The half-life can be adjusted by changing the PS affinity for ATIII. (Chemical Equation Presented) © 2008 Wiley-VCH Verlag GmbH & Co. KGaA.

引用

页码：1189 / 1193

页数：5

共 49 条

[1] Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization [J].

Bai, Yun ;

Shen, Wei-Chiang .

PHARMACEUTICAL RESEARCH, 2006, 23 (09) :2116-2121

[2]

Beals John M, 2006, Drug Discov Today Technol, V3, P87, DOI 10.1016/j.ddtec.2006.03.001

[3]

Boeckel V., 2005, Eur. Pat. Appl, Patent No. 1574516

[4]

Bos ES, 2006, PCT. Pat. Appl, Patent No. [WO/2006/082184, 2006082184]

[5]

Büller HR, 2000, CIRCULATION, V102, P2726

[6]

Chuang VTG, 2002, PHARMACEUT RES, V19, P569

[7] Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes [J].

Danne, T ;

Lüpke, K ;

Walte, K ;

von Schuetz, W ;

Gall, MA .

DIABETES CARE, 2003, 26 (11) :3087-3092

[8] Synthetic heparin derivatives as new anticoagulant drugs [J].

de Kort, M ;

Buijsman, RC ;

van Boeckel, CAA .

DRUG DISCOVERY TODAY, 2005, 10 (11) :769-779

[9] Insulin receptor internalization and signalling [J].

Di Guglielmo, GM ;

Drake, PG ;

Baass, PC ;

Authier, F ;

Posner, BI ;

Bergeron, JJM .

MOLECULAR AND CELLULAR BIOCHEMISTRY, 1998, 182 (1-2) :59-63

[10] The pharmacokinetics of fondaparinux sodium in healthy volunteers [J].

Donat, F ;

Duret, JP ;

Santoni, A ;

Cariou, R ;

Necciari, J ;

Magnani, H ;

de Greef, R .

CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 2) :1-9

← 1 2 3 4 5 →